El interés en corto de Mesoblast da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Mesoblast. Los datos de interés en corto se actualizan cada dos semanas.

Mesoblast (NASDAQ:MESO) Bolsa, Informe de interés en corto

Mesoblast

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

AADI

APTO

CADL

CARA

HUMA

MESO

MOBX

MTEM

NVNI

OCEA

PRFX

QUBT

ZCAR

FedEx sube un 8,7% con resultados sólidos y una nueva estrategia. Descubre otras acciones destacadas en premercado hoy.

Las acciones de FedEx (FDX) suben alrededor de un 9%; 20 acciones que se mueven en premercado

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEMD

APCX

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

DALN

DSGN

ELAB

KULR

LITM

PTPI

QNTM

SGMO

SLXN

VRAX

Acciones de Sangamo Therapeutics suben un 19,5% tras un nuevo acuerdo. Descubre los mayores ganadores y perdedores de hoy.

Acciones de Sangamo Therapeutics (SGMO) suben alrededor de un 20%; 20 acciones que se mueven en el premercado

Mesoblast Limited - American Depositary Shares

Mesoblast Ltd

Meso Numismatics Inc

WIIM

DTCK

Davis Commodities shares are trading higher after the company announced approval of a $30 million fundraising plan to establish bitcoin reserves to strengthen asset allocation.

The May employment report delivered a stronger-than-expected performance, fueling optimism across markets and a full-throated celebration from President Donald Trump—who simultaneously stepped up his public campaign to push Federal Reserve Chair Jerome Powell <a href="https://www.benzinga.com/markets/economic-data/25/06/45812372/us-labor-markets-defies-tariff-concerns-as-nonfarm-payrolls-wages-top-expectations-in-may">toward cutting interest rates.</a>
Nonfarm payrolls rose by 139,000 last month, topping forecasts of 130,000. Wage growth also beat expectations, with average hourly earnings climbing 0.4% month over month and 3.9% year over year. The unemployment rate held steady at 4.2%.
Trump reacted swiftly on Truth Social, hailing the numbers as proof of the economy's continued strength under his leadership: 
&#8220;Great job number, stock market up big!,&#8221; Trump wrote. 
But beyond celebration, the president issued another sharp call for aggressive monetary easing, targeting Powell directly.
"‘Too Late' at the Fed is a disaster!" Trump posted. 
"Europe has had 10 rate cuts, we have had none. Despite him, our Country is doing great. Go for a full point, Rocket Fuel!" 
He added that "borrowing costs should be much lower," indicating that inflation is no longer a concern and that delaying action would "cost our Country a fortune."
<h3 class="wp-block-heading">Economists Say Fed Can Take Its Time</h3>
Despite Trump&#8217;s renewed pressures on Powell, most economists reading the May jobs report say the data gives the Federal Reserve more reason to remain cautious—not less.
Economist Mohamed El-Erian said the report sent a "clear message" that the central bank can afford to delay any cuts, given that "both May job creation and wage growth were higher than consensus forecasts."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">One clear message from today's US jobs report is that, whatever the average expectations were for Fed rate cuts, they should now be somewhat smaller and somewhat later. Why? Because BOTH May job creation AND wage growth were higher than the consensus forecasts. Specifically, Job…
&mdash; Mohamed A. El-Erian (@elerianm) <a href="https://twitter.com/elerianm/status/1930984774111199441?ref_src=twsrc%5Etfw">June 6, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Bill Adams, economist of Comerica Bank struck a similar tone, suggesting "the Fed will notice deterioration at the edges," but not enough to justify action in the near term.
Steve Wyett, chief investment strategist at BOK Financial noted the "deleterious impacts of uncertain tariff policies have yet to be fully reflected," adding that while the Fed remains in a holding pattern, the door remains open to cuts later this year.
Jeffrey Roach, chief economist at LPL Financial described the labor market's slowdown as "quite smooth so far without many surprises." He said that, although payroll growth is moderating, the economy remains on stable footing and the Fed has no reason to act quickly.
Money markets now expect the first interest rate cut to come by October 2025, with CME Group's FedWatch tool showing an 83% chance of a second cut in December.
<h3 class="wp-block-heading">Markets Rally In Response, Treasury Yields Rise</h3>
Investors welcomed the report. 
The S&amp;P 500 – as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – broke above 6,000 points, rising 1.1% on Friday. The Nasdaq 100 gained 1.2% to 21,800. The tech-heavy index now trades at less than 2 percentage points below record highs. 
The bond market responded with higher yields, as traders dialed back expectations for imminent Fed action. The 10-year Treasury yield climbed 6 basis points to 4.47%, while the 30-year yield rose 5 points to 4.93%. 
The U.S. dollar index gained 0.5%, and gold slipped 0.9% to $3,330 an ounce.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/45777617/peak-pessimism-on-us-treasuries-history-says-a-summer-rally-may-be-near">Peak Pessimism On US Treasuries? History Says A Summer Rally May Be Near </a></li>
</ul>
Image created using photos from Shutterstock.

Analyst Color

Government

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Econ #s

Economics

Federal Reserve

Analyst Ratings

ETFs

Trump Cheers Strong Jobs Data, Renews Attack On Fed's Powell: Rates 'Should Be Much Lower'

A Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) analyst cuts delivery estimates for the electric vehicle giant as more reports<a href="https://www.benzinga.com/markets/eurozone/25/06/45736798/tesla-sales-hit-3-year-low-in-this-european-nation-despite-musks-claims-of-no-demand-problem"> show weakened demand.</a>
The Tesla Analyst: Goldman Sachs analyst Mark Delaney maintained a Neutral rating on Tesla and lowered the price target from $295 to $285.
Read Also: <a href="https://www.benzinga.com/news/earnings/25/04/44937440/tesla-q1-misses-estimates-as-tariff-pressures-weigh-on-outlook-lower-cost-evs-still-on-track">Tesla Q1 Misses Estimates As Tariff Pressures Weigh On Outlook, Lower-Cost EVs Still On Track</a>
The Analyst Takeaways: Tesla is showing weak demand in several top countries, Delaney said in a new investor note.
"We're lowering our Tesla vehicle delivery assumptions and EPS estimates to better reflect weaker monthly datapoints in key regions, and also consumer survey data on Tesla."
The analyst highlights quarter-to-date deliveries in the U.S. down mid-teens year-over-year. Registration data in Europe shows a 50% year-over-year decline for the month of April. In China, demand is also declining based on key data points.
"We believe 2Q deliveries could end up between 335k and 395k, depending on how strong June results are, and our base case view is now 365k deliveries for 2Q25."
This base case estimate is down from a previous estimate of 410k deliveries and below the consensus estimate of 417k, according to the report. Along with lowering second-quarter deliveries, the analyst also cuts estimates for 2025, 2026 and 2027 to "better reflect recent vehicle sales datapoints and demand trends."
The analyst said consumer data on sentiment and hearing positive things about the electric vehicle company is weak for Tesla in North America and Europe, but remains stronger in China.
"This suggests to us that demand/brand issues may be contributing to weakness in the US and European markets, and the decline QTD in China could be the result of competition and product cycle timing."
Delaney estimates that 2024 deliveries were split as 30% U.S., 37% China, 18% Europe and 10% other geographies.
While the analyst has a price target of $285, the investor report lays out a downside valuation scenario that could take the stock to $150.
TSLA Price Action: Tesla stock is up 5.36% to $300.54 on Friday versus a 52-week trading range of $167.41 to $488.54. Tesla stock is down 21.8% year-to-date in 2025, with shares falling around 13% in the last five days.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45805173/musk-vs-trump-tesla-suffers-record-152b-one-day-crash-as-ceo-warns-tariffs-will-cause-a-recession">Musk Vs. Trump: Tesla Suffers Record $152B One-Day Crash As CEO Warns Tariffs &#8216;Will Cause A Recession&#8217;</a></li>
</ul>
Photo: Courtesy Tesla

Price Target

Reiteration

TSLA

Tesla Stock Faces 'Demand/Brand Issues' In US, Competition In China: Analyst Lowers Delivery Estimates

PHAT

Phathom Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 59.1%

Institutional Shareholder Services ("ISS") Recommends Shareholders Cast Votes Using the GOLD Proxy Card "FOR" William Clifford, Johnny Hartnett and Carlos Ruisanchez at PENN's 2025 Annual Meeting
ISS Finds a Clear Case for Meaningful Change at PENN; Highlights that PENN has "Underperformed Peers Across the Board" and Raises "Concerns About its Approach to Refreshment"
ISS States the Independent Director Nominees Would Bring "Direct Gaming Industry Experience" to PENN's Board
HG Vora Urges Shareholders to Vote "FOR" All Three Independent Candidates on the GOLD Proxy Card to Express Their Desire for Genuine, Shareholder-Driven Change at PENN
HG Vora Capital Management, LLC (together with its affiliates, "HG Vora") today announced that Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy advisory firm, has recommended that shareholders of PENN Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>) ("PENN" or the "Company") cast their votes "FOR" the election of all three independent director candidates nominated by HG Vora – William Clifford, Johnny Hartnett, and Carlos Ruisanchez – to the Company's Board of Directors (the "Board") on the GOLD proxy card at PENN's 2025 Annual Meeting of Shareholders (the "Annual Meeting"), scheduled for June 17, 2025.

Management

PENN

ISS Recommends Shareholders Vote "FOR" All Three HG Vora Nominees At PENN's 2025 Annual Meeting, Citing Underperformance, Board Refreshment Concerns, And Need For Gaming Industry Expertise

Rumors

Watching Phathom Pharmaceuticals; Shares Spike Higher, Traders Circulate FDA Has Granted The Co The 10 Year NCE Exclusivity And The Correction To The Orange Book Listings For 10 Mg & 20 Mg Voquezna Tablets To Reflect Full 10-Year NCE Exclusivity Through May 3, 2032

IPOs

OMDA

Omada Health Shares Open For Trade At $23/Share; IPO Priced At $19/Share

ARVN

Arvinas shares are trading higher after the company announced its submission of an NDA to the FDA for Vepdegestrant

DocuSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) shares are trading lower Friday. The company reported first-quarter financial results on Thursday after <a href="https://www.benzinga.com//node/45802285">the market closed</a>.
The Details: DocuSign reported earnings per share of 90 cents, beating the consensus estimate of 81 cents. In addition, the company reported sales of $763.70 million, beating the consensus estimate of $748.13 million, representing a 8% year-over-year climb.
The company broke down sales further, reporting subscription revenue was $746.2 million, an 8% year-over-year increase, and professional services and other revenue was $17.5 million, a 4% rise year-over-year.
DocuSign also announced a $1 billion increase to its share repurchase authorization, bringing the total remaining authorization to $1.4 billion.
The company ended the quarter with $1.1 billion in cash, cash equivalents and restricted cash and investments.
&#8220;Q1&nbsp;was an important quarter for Docusign&#8217;s long-term transformation as we delivered on an ambitious product roadmap and surpassed 10,000 Intelligent Agreement Management customers,&#8221; said&nbsp;Allan Thygesen, CEO of Docusign.
Outlook: The company sees second-quarter sales from $777 million to $781 million, versus the consensus estimate of $774.75 million.
DocuSign now sees fiscal-year sales from $3.15 billion to $3.16 billion, versus the consensus estimate of $3.14 billion. The company previously expected sales from $3.13 billion to $3.14 billion.
Following the earnings report, Wedbush analyst Daniel Ives maintained a Neutral rating on DocuSign and lowered the price target from&nbsp;$100&nbsp;to&nbsp;$85.
Related Link: <a href="https://www.benzinga.com/markets/market-summary/25/06/45814267/dow-jumps-over-500-points-nonfarm-payrolls-top-estimates">Dow Jumps Over 500 Points; Nonfarm Payrolls Top Estimates</a>
DOCU Price Action: At the time of publication, DocuSign stock is trading 18.4% lower at $75.81, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwjT9p_c_NyNAxWok4kEHbkOLfYQFnoECBEQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.
Image: via Shutterstock

DOCU

DocuSign Shares Are Falling Friday: What's Going On?

S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) has outperformed the market over the past 10 years by 6.44% on an annualized basis producing an average annual return of 17.4%. Currently, S&amp;P Global has a market capitalization of $159.28 billion. 
Buying $100 In SPGI: If an investor had bought $100 of SPGI stock 10 years ago, it would be worth $502.19 today based on a price of $519.37 for SPGI at the time of writing.
<h3>S&amp;P Global's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749224718_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SPGI

Here's How Much $100 Invested In S&P Global 10 Years Ago Would Be Worth Today

Shares of Chinese electric vehicle manufacturer NIO Inc &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) were trading flat Friday morning at $3.60. The stock has been volatile this week following the release of the company&#8217;s first-quarter <a href="https://www.benzinga.com/markets/large-cap/25/06/45745834/nio-stock-drops-after-q1-results-and-outlook-disappoints-the-street-margins-shrink">earnings report</a> before the bell on Tuesday.
What To Know: NIO reported first-quarter revenue of $1.37 billion, representing a decrease of 7.2% year-over-year and missing the analyst consensus estimate of $1.48 billion.
The company <a href="https://www.benzinga.com/markets/tech/25/06/45775689/tesla-rival-nio-says-it-will-cut-rd-spending-by-around-25-to-meet-breakeven-target-amid-europe-expansion-plans">announced</a> a quarterly adjusted loss of 36 cents per share, which was wider than the analyst consensus estimate for a loss of 31 cents per share.
Vehicle deliveries for the quarter totaled 30,053, a decrease of 3.2% year-over-year. The company&#8217;s vehicle margin was 9.2%, while the overall gross margin came in at 4.9%.
Looking ahead, NIO expects to deliver between 54,000 and 56,000 vehicles in the second quarter. The company issued second-quarter revenue guidance of between $2.29 billion and $2.36 billion.
Read Also: <a href="https://www.benzinga.com/news/sports/25/06/45812523/manchester-united-stock-jumps-after-q3-profit-turnaround-matchday-growth-and-stadium-plans">Manchester United Stock Jumps After Q3 Profit Turnaround, Matchday Growth, And Stadium Plans</a>
<h2 class="wp-block-heading">How To Buy NIO Stock</h2>
By now you're likely curious about how to participate in the market for NIO &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NIO has a 52-week high of $7.71 and a 52-week low of $3.02.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45809783/us-stocks-likely-to-open-higher-traders-have-become-jaded-about-trumps-tumultuous-trade-dealmaking-says-expert" target="_blank" rel="noreferrer noopener">US Stocks Likely To Open Higher: ‘Traders Have Become Jaded About Trump's Tumultuous Trade Dealmaking,' Says Expert</a></li>
</ul>
Image: Shutterstock

NIO Stock Volatile After Mixed Q1 Earnings, Cost Cuts And Global Expansion In Focus

RBC Capital analyst Nik Modi maintains Brown-Forman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) with a Sector Perform and lowers the price target from $44 to $30.

BF/B

RBC Capital Maintains Sector Perform on Brown-Forman, Lowers Price Target to $30

Oil-Dri Corporation Of America shares are trading higher after the company reported better-than-expected Q3 financial results.

WisdomTree&#8216;s head of product Jason Guthrie says the blockchain industry is in its &#8220;selling books&#8221; phase similar to Amazon&#8217;s early days, with massive expansion ahead as financial services adopt on-chain infrastructure to reduce costs <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45798988/could-bitcoin-plummet-to-90000-soon">and improve efficiency.</a>
&#8220;Right now as an industry we&#8217;re selling books but we&#8217;re going to go into all of these new spaces,&#8221; Guthrie told Benzinga at Consensus 2025, drawing parallels between crypto&#8217;s current state and Amazon&#8217;s evolution from bookseller to cloud computing giant. 
&#8220;Anyone that saw Amazon in the &#8217;90s would never have pictured AWS.&#8221;
WisdomTree, a traditional asset management firm with $115 billion in assets under management, has been expanding into digital assets over the past four to five years through a dedicated division focused on bringing &#8220;real-world exposures on chain.&#8221; 
Read Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45798988/could-bitcoin-plummet-to-90000-soon">Could Bitcoin Plummet To $90,000 Soon?</a>
Guthrie emphasized that blockchain&#8217;s value proposition centers on &#8220;smoothing out workflows and improving capital efficiency and transparency,&#8221; while maintaining regulatory compliance.
The executive addressed skeptics by highlighting the organic innovation emerging from the crypto space. 
&#8220;Do a little bit of research and have a look at just the amount of organic innovation that we&#8217;ve seen,&#8221; he advised. 
Rather than pursuing complete disintermediation, Guthrie envisions a more nuanced evolution of financial services. 
Guthrie predicts &#8220;a consolidation of providers,&#8221; which should leverage internet-native infrastructure to deliver fundamental services for investing.
The executive emphasized that blockchain adoption requires patience and incremental progress. &#8220;No technology innovation comes in overnight,&#8221; he cautioned.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45810884/bitcoin-ethereum-xrp-dogecoin-extend-losses-after-trump-musk-fallout">Bitcoin, Ethereum, XRP, Dogecoin Extend Losses After Trump-Musk Fallout</a></li>
</ul>
 Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Exclusives

Blockchain's AWS Moment Is Coming, Says WisdomTree's Jason Guthrie

SLDB

Solid Biosciences shares are trading higher after JMP Securities reiterated its Market Outperform rating on the stock and maintained a $15 price target.

Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 434,720 shares of common stock at a purchase price of $2.65 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered short-term warrants to purchase up to 869,440 shares of common stock at an exercise price of $2.65 per share that will be immediately exercisable upon issuance and will expire eighteen months following the effective date of the registration statement covering the resale of the shares of common stock issuable upon exercise of the unregistered short-term warrants. The closing of the offering is expected to occur on or about June 9, 2025, subject to the satisfaction of customary closing conditions.
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.
The gross proceeds to the Company from the offering are expected to be approximately&nbsp;$1.15 million, before deducting placement agent fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the unregistered short-term warrants, if fully-exercised on a cash basis, will be approximately $2.3 million. No assurance can be given that any of such unregistered short-term warrants will be exercised. The Company intends to use the net proceeds from the offering for general corporate purposes.

Offerings

VERO

Venus Concept Announces $1.15M Registered Direct Offering Of Common Stock At $2.65/Share And Concurrent Private Placement Of Unregistered Warrants For Up To $2.3M In Potential Proceeds

JP Morgan analyst Tessa Romero maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Overweight and raises the price target from $26 to $30.

ACAD

JP Morgan Maintains Overweight on ACADIA Pharmaceuticals, Raises Price Target to $30

HIVE

HIVE Digital Technologies shares are trading higher after the company it achieved a 58% peak hash rate growth in one month

Pony AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45808958/pony-ai-accelerates-gen-7-robotaxi-deployment-with-road-testing-launch-in-chinas-guangdong" rel="noreferrer noopener">announced on Friday</a> that it is ramping up its Robotaxi mass production and commercialization efforts by launching public road testing for its seventh-generation Robotaxis in&nbsp;China.
The vehicles tested on roads in the southern Chinese megacities of&nbsp;Guangzhou&nbsp;and&nbsp;Shenzhen&nbsp;are based on Guangzhou Auto(GAC)&#8217;s second-generation Aion V model and are equipped with&nbsp;Pony.ai&#8217;s advanced autonomous driving system.&nbsp;
The autonomous driving technology company&nbsp;recently obtained a regulatory permit to conduct these road tests for its seventh-generation Robotaxi, which was jointly developed with GAC.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/45718402/pony-ai-xihu-group-to-deploy-over-1000-robotaxis-in-shenzhen" rel="noreferrer noopener">Pony.ai, Xihu Group To Deploy Over 1,000 Robotaxis In Shenzhen</a>
&nbsp;At the Shanghai Auto Show, Pony.ai&nbsp;debuted its Gen-7 autonomous driving system in April.
To support widespread adoption,&nbsp;Pony.ai&nbsp;has established deep commercial partnerships with global leaders in technology, mobility services, and deployment platforms, including&nbsp;Tencent Holding (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCEHY#OTC">TCEHY</a>) Tencent&nbsp;Cloud, Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) Alipay and Amap.
Pony AI&#8217;s <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45514486/chinas-pony-ai-robotaxi-revenue-jumps-200-eyes-1000-vehicle-fleet" rel="noreferrer noopener">first-quarter sales</a>&nbsp;grew 11.6% to $13.98 million (101.6 million Chinese yuan), mainly driven by rapid growth in Robotaxi services revenues. The analyst consensus estimate for sales was 90.11 million Chinese yuan. Robotaxi services&nbsp;revenue climbed 200.3% to $1.7 million in the quarter, primarily attributable to expanding its public-facing fare-charging operations in Tier-one cities in China and refined operational strategies for diverse user groups.
Also this week, Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/45740083/elon-musks-tesla-files-new-autonomous-taxi-trademark-application-ahead-of-robotaxi-launch-in-june" rel="noreferrer noopener">filed a fresh</a> trademark application for the wordmark &#8220;Tesla Robotaxi&#8221; with the U.S. Patent and Trademark Office (USPTO) after the&nbsp;agency previously rejected&nbsp;its application.
The EV giant is gearing up to launch its Robotaxi services in Austin on June 12. Tesla CEO Elon Musk previously stated that the launch would initially involve over 10-20 Model Ys.
Price Action: PONY shares are trading higher by 1.9% to $13.74 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/small-cap/25/06/45795738/blink-charging-appoints-new-cfo-to-help-steer-turnaround" target="_blank" rel="noreferrer noopener">Blink Charging Appoints New CFO To Help Steer Turnaround</a></li>
</ul>
Photo: Shutterstock

Asia

BABA

PONY

TCEHY

Pony.ai Begins Testing Futuristic Robotaxis In China, Mass Rollout Could Be Next

Quantum Computing shares are trading higher after Ascendiant Capital maintained its Buy rating on the stock and raised the price target from $14 to $22.

Press Releases

General

Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States

Ryoncil® is Now Available for Purchase in the United States

Health Care

First Three Children to Commence Treatment With Ryoncil®

Stem Cell Innovators: 4 Companies Advancing Regenerative Medicine

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

Politics

Mesoblast Allogeneic Cell Therapy Products Are Designated 'U.S. Country of Origin' and Not Subject to U.S. Tariffs

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

Earnings

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

ADIA

CRSP

FATE

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Beam Therapeutics

Biohaven

CareDx

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Dyne Therapeutics

89bio

Amicus Therapeutics

Galapagos NV - American Depositary Shares

Galapagos

GRAIL

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Disc Medicine

Janux Therapeutics

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

MannKind

Novavax

Arcus Biosciences

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

ARS Pharmaceuticals

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Piper Sandler

Maxim Group

Chardan Capital

Screenshot 2024-11-15 at 7.50.34 PM

Biotech

BCLI

BRTX

LGVN

Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative&#39;s Inroads Bringing Its Stem Cell Therapies To Market

Comments

Mesoblast

Interés en corto

Mesoblast (NASDAQ:MESO) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL